How many drugs treat Metastatic Prostate Carcinoma?

Drug Landscape tracks 9 marketed treatments for Metastatic Prostate Carcinoma (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Metastatic Prostate Carcinoma?

Most recent: Estring — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/metastatic-prostate-carcinoma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

Metastatic Prostate Carcinoma — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Metastatic Prostate Carcinoma (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Metastatic Prostate Carcinoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Jevtana Kit	cabazitaxel	Accord Hlthcare	Microtubule Inhibitor	Tubulin beta	2010-01-01
Nilandron	NILUTAMIDE	Advanz	Androgen Receptor Inhibitor [EPC]	Androgen receptor	1996-01-01
Casodex	bicalutamide	ANI Pharmaceuticals	Androgen Receptor Inhibitor [EPC]	Androgen receptor	1995-01-01
Depoestradiol	ESTRADIOL CYPIONATE	Pfizer	Estrogen	Estrogen receptor beta	1979-01-01
Estrace	ESTRADIOL	Pfizer	Estrogen	Estrogen receptor	1975-01-01
Delestrogen	ESTRADIOL VALERATE	Ph Health	Estrogen	Estrogen receptor	1954-01-01
Mitozantrone	Mitozantrone	US Department of Veterans Affairs		Canalicular multispecific organic anion transporter 1, ATP-binding cassette sub-family G member 2, DNA-(apurinic or apyrimidinic site) lyase
Jevtana	Jevtana	Bayer		Tubulin beta
Casodex	Casodex	University Health Network, Toronto		Cytochrome P450 2C19, Androgen receptor, Androgen receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-05-11 — Estring · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 2 drugs in Metastatic Prostate Carcinoma
ANI Pharmaceuticals · 1 drug in Metastatic Prostate Carcinoma
Accord Hlthcare · 1 drug in Metastatic Prostate Carcinoma
Advanz · 1 drug in Metastatic Prostate Carcinoma
Bayer · 1 drug in Metastatic Prostate Carcinoma
Pfizer Inc. · 1 drug in Metastatic Prostate Carcinoma
Ph Health · 1 drug in Metastatic Prostate Carcinoma
US Department of Veterans Affairs · 1 drug in Metastatic Prostate Carcinoma
· 1 drug in Metastatic Prostate Carcinoma
University Health Network, Toronto · 1 drug in Metastatic Prostate Carcinoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Metastatic Prostate Carcinoma:

Cite this brief

Drug Landscape (2026). Metastatic Prostate Carcinoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/metastatic-prostate-carcinoma. Accessed 2026-06-09.

Metastatic Prostate Carcinoma full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing